Inozyme Pharma Inc (INZY) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Inozyme Pharma Inc

NASDAQ | INZY

0.87

USD

-0.0561 (-6.06%)

AT CLOSE (AS OF Apr 3, 2025)

$60M

MARKET CAP

P/E Ratio

-1.62

EPS

52 Week High

$0.83

52 Week Low

LIFE SCIENCES

Sector

INZY Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

INZY Technicals

Tags:

INZY Earnings

Yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	-$25M
Total Revenue	-
Cost Of Revenue	$22M
Costof Goods And Services Sold	$1.3M
Operating Income	-$76M
Selling General And Administrative	$21M
Research And Development	$55M
Operating Expenses	$76M
Investment Income Net	$7.8M
Net Interest Income	-$3.3M
Interest Income	$4.1M
Interest Expense	$3.3M
Non Interest Income	-
Other Non Operating Income	-$28K
Depreciation	$833K
Depreciation And Amortization	$800K
Income Before Tax	-$71M
Income Tax Expense	$0
Interest And Debt Expense	$3.3M
Net Income From Continuing Operations	-$71M
Comprehensive Income Net Of Tax	-$71M
Ebit	-$68M
Ebitda	-$67M
Net Income	-$71M

Revenue & Profitability

Earnings Performance

INZY Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2023)

Field	Value (USD)
Total Assets	$201M
Total Current Assets	$196M
Cash And Cash Equivalents At Carrying Value	$35M
Cash And Short Term Investments	$189M
Inventory	-
Current Net Receivables	$385K
Total Non Current Assets	$4.6M
Property Plant Equipment	$1.5M
Accumulated Depreciation Amortization Ppe	$2.4M
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	-
Investments	$154M
Long Term Investments	$0
Short Term Investments	$154M
Other Current Assets	-
Other Non Current Assets	-
Total Liabilities	$60M
Total Current Liabilities	$15M
Current Accounts Payable	$1.2M
Deferred Revenue	-
Current Debt	-
Short Term Debt	-
Total Non Current Liabilities	$913K
Capital Lease Obligations	-
Long Term Debt	$45M
Current Long Term Debt	$0
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$45M
Other Current Liabilities	-
Other Non Current Liabilities	$0
Total Shareholder Equity	$140M
Treasury Stock	-
Retained Earnings	-
Common Stock	$6K
Common Stock Shares Outstanding	$62M

yearly Cash Flow (As of Dec 31, 2023)

Field	Value (USD)
Operating Cashflow	-$71M
Payments For Operating Activities	$2.3M
Proceeds From Operating Activities	-
Change In Operating Liabilities	-$1.1M
Change In Operating Assets	$4.1M
Depreciation Depletion And Amortization	-$4M
Capital Expenditures	$298K
Change In Receivables	-
Change In Inventory	-
Profit Loss	-$71M
Cashflow From Investment	-$54M
Cashflow From Financing	$126M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	$40M
Dividend Payout Common Stock	$40M
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	$86M
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	$40M
Proceeds From Issuance Of Preferred Stock	$0
Proceeds From Repurchase Of Equity	$86M
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$71M

yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	-$25M
Total Revenue	-
Cost Of Revenue	$22M
Costof Goods And Services Sold	$1.3M
Operating Income	-$76M
Selling General And Administrative	$21M
Research And Development	$55M
Operating Expenses	$76M
Investment Income Net	$7.8M
Net Interest Income	-$3.3M
Interest Income	$4.1M
Interest Expense	$3.3M
Non Interest Income	-
Other Non Operating Income	-$28K
Depreciation	$833K
Depreciation And Amortization	$800K
Income Before Tax	-$71M
Income Tax Expense	$0
Interest And Debt Expense	$3.3M
Net Income From Continuing Operations	-$71M
Comprehensive Income Net Of Tax	-$71M
Ebit	-$68M
Ebitda	-$67M
Net Income	-$71M

INZY Profile

Inozyme Pharma Inc Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, is dedicated to developing therapies for the treatment of abnormal mineralization that impacts the vasculature, soft tissue, and skeletal diseases. The company is headquartered in Boston, Massachusetts.

Most Active

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	13.04%	-	706,860,781
NVDA	$103.14	-6.59%	$2.68T	263,349,217
LCID	$2.34	-2.30%	$7.67B	187,389,814
F	$9.68	-4.68%	$39.53B	173,285,336
PTIX	$0.43	91.50%	$4.04M	173,208,693

See more →

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.76	1.92%	$399.61B	6,083,153
NVO	$67.60	-0.95%	$308.32B	7,033,051
AZN	$74.03	2.50%	$225.70B	6,150,517
MRK	$86.76	0.18%	$220.07B	7,844,359

See more →

Top Gainers

Symbol	Price	Change %	Market Cap	Volume
VCIG	$6.06	1,818.33%	$26.40M	302,396
MKTW	$9.19	1,684.81%	$19.91M	117,875
ICCT	$4.38	111.59%	$9.78M	168,784,937
PTIX	$0.43	91.50%	$4.04M	173,208,693
MRM	$0.65	74.84%	$2.91M	51,693,935

See more →

Top Losers

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	20,249,631
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669